{"id":19407,"date":"2020-10-12T05:13:25","date_gmt":"2020-10-11T21:13:25","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=19407"},"modified":"2020-10-19T06:10:06","modified_gmt":"2020-10-18T22:10:06","slug":"nejm%e5%9c%a8%e7%ba%bf%e5%8f%91%e8%a1%a8%ef%bc%9abeta-1b%e5%b9%b2%e6%89%b0%e7%b4%a0%e8%81%94%e5%90%88%e5%85%8b%e7%ab%8b%e8%8a%9d%e6%b2%bb%e7%96%97%e4%b8%ad%e4%b8%9c%e5%91%bc%e5%90%b8%e7%bb%bc","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=19407","title":{"rendered":"[NEJM\u5728\u7ebf\u53d1\u8868]\uff1aBeta-1b\u5e72\u6270\u7d20\u8054\u5408\u514b\u7acb\u829d\u6cbb\u7597\u4e2d\u4e1c\u547c\u5438\u7efc\u5408\u5f81"},"content":{"rendered":"\n

ORIGINAL ARTICLE<\/a><\/p>\n\n\n\n

Interferon Beta-1b and Lopinavir\u2013Ritonavir for Middle East Respiratory Syndrome<\/h1>\n\n\n\n

Yaseen M. Arabi, Ayed Y. Asiri, Abdullah M. Assiri, et al<\/h3>\n\n\n\n

N Engl J Med October 7, 2020
DOI: 10.1056\/NEJMoa2015294<\/h3>\n\n\n\n

Abstract \u6458\u8981<\/h2>\n\n\n\n

BACKGROUND \u80cc\u666f<\/h3>\n\n\n\n

Whether combined treatment with recombinant interferon beta-1b and lopinavir\u2013ritonavir reduces mortality among patients hospitalized with Middle East respiratory syndrome (MERS) is unclear.<\/p>\n\n\n\n

\u91cd\u7ec4beta-1b\u5e72\u6270\u7d20\u4e0e\u514b\u7acb\u829d\u8054\u5408\u6cbb\u7597\u80fd\u5426\u964d\u4f4e\u4e2d\u4e1c\u547c\u5438\u7efc\u5408\u5f81(MERS)\u4f4f\u9662\u60a3\u8005\u75c5\u6b7b\u7387\u5c1a\u4e0d\u6e05\u695a\u3002<\/p>\n\n\n\n

METHODS \u65b9\u6cd5<\/h3>\n\n\n\n

We conducted a randomized, adaptive, double-blind, placebo-controlled trial that enrolled patients at nine sites in Saudi Arabia. Hospitalized adults with laboratory-confirmed MERS were randomly assigned to receive recombinant interferon beta-1b plus lopinavir\u2013ritonavir (intervention) or placebo for 14 days. The primary outcome was 90-day all-cause mortality, with a one-sided P-value threshold of 0.025. Prespecified subgroup analyses and safety analyses were conducted. Because of the pandemic of coronavirus disease 2019, the data and safety monitoring board requested an unplanned interim analysis and subsequently recommended the termination of enrollment and the reporting of the results.<\/p>\n\n\n\n

\u6211\u4eec\u8fdb\u884c\u4e86\u4e00\u9879\u968f\u673a\u3001\u9002\u5e94\u6027\u3001\u53cc\u76f2\u3001\u5b89\u6170\u5242\u5bf9\u7167\u8bd5\u9a8c\uff0c\u5728\u6c99\u7279\u963f\u62c9\u4f2f\u76849\u4e2a\u4e2d\u5fc3\u5165\u9009\u60a3\u8005\u3002\u6211\u4eec\u5c06\u5b9e\u9a8c\u5ba4\u786e\u8bca\u7684MERS\u6210\u5e74\u60a3\u8005\u968f\u673a\u5206\u7ec4\uff0c\u5206\u522b\u63a5\u53d7\u91cd\u7ec4beta-1b\u5e72\u6270\u7d20\u8054\u5408\u514b\u7acb\u829d\uff08\u5e72\u9884\u7ec4\uff09\u6216\u5b89\u6170\u5242\uff0c\u7597\u7a0b14\u5929\u3002\u4e3b\u8981\u9884\u540e\u6307\u6807\u4e3a90\u5929\u5168\u56e0\u75c5\u6b7b\u7387\uff0c\u5355\u5c3eP\u503c0.025\u3002\u6211\u4eec\u8fdb\u884c\u4e86\u9884\u5148\u786e\u5b9a\u7684\u4e9a\u7ec4\u5206\u6790\u53ca\u5b89\u5168\u6027\u5206\u6790\u3002\u7531\u4e8e\u65b0\u51a0\u75c5\u6bd2\u611f\u67d3\u75ab\u60c5\u7206\u53d1\uff0c\u6570\u636e\u53ca\u5b89\u5168\u76d1\u7763\u59d4\u5458\u4f1a\u8981\u6c42\u8fdb\u884c\u8ba1\u5212\u5916\u7684\u4e2d\u671f\u5206\u6790\uff0c\u968f\u540e\u5efa\u8bae\u7ec8\u6b62\u60a3\u8005\u5165\u9009\u5e76\u62a5\u544a\u7ed3\u679c\u3002<\/p>\n\n\n\n

RESULTS \u7ed3\u679c<\/h3>\n\n\n\n

A total of 95 patients were enrolled; 43 patients were assigned to the intervention group and 52 to the placebo group. A total of 12 patients (28%) in the intervention group and 23 (44%) in the placebo group died by day 90. The analysis of the primary outcome, with accounting for the adaptive design, yielded a risk difference of \u221219 percentage points (upper boundary of the 97.5% confidence interval [CI], \u22123; one-sided P=0.024). In a prespecified subgroup analysis, treatment within 7 days after symptom onset led to lower 90-day mortality than use of placebo (relative risk, 0.19; 95% CI, 0.05 to 0.75), whereas later treatment did not. Serious adverse events occurred in 4 patients (9%) in the intervention group and in 10 (19%) in the placebo group.<\/p>\n\n\n\n

\u5171\u5165\u900995\u540d\u60a3\u8005\uff1b43\u540d\u60a3\u8005\u5206\u81f3\u5e72\u9884\u7ec4\uff0c52\u540d\u60a3\u8005\u5206\u81f3\u5b89\u6170\u5242\u7ec4\u3002\u5e72\u9884\u7ec412\u540d(28%)\u60a3\u8005\u53ca\u5b89\u6170\u5242\u7ec423\u540d(44%)\u60a3\u8005\u572890\u5929\u5185\u6b7b\u4ea1\u3002\u6839\u636e\u9002\u5e94\u6027\u8bbe\u8ba1\u8fdb\u884c\u6821\u6b63\u540e\uff0c\u4e3b\u8981\u9884\u540e\u6307\u6807\u98ce\u9669\u5dee\u5f02\u4e3a19\u4e2a\u767e\u5206\u70b9\uff0897.5%\u53ef\u4fe1\u533a\u95f4 [CI] \u4e0a\u9650, \u22123; \u5355\u5c3eP=0.024\uff09\u3002\u5728\u9884\u5148\u786e\u5b9a\u7684\u4e9a\u7ec4\u5206\u6790\u4e2d\uff0c\u53d1\u75c57\u5929\u5185\u8fdb\u884c\u6cbb\u7597\u4f34\u968f90\u5929\u75c5\u6b7b\u7387\u964d\u4f4e\uff08\u76f8\u5bf9\u5371\u9669\u5ea6, 0.19; 95% CI, 0.05 to 0.75\uff09\uff0c\u800c\u5ef6\u8fdf\u6cbb\u7597\u5219\u4e0d\u7136\u3002\u5e72\u9884\u7ec44\u540d(9%)\u60a3\u8005\u4e0e\u5b89\u6170\u5242\u7ec410\u540d(19%)\u60a3\u8005\u53d1\u751f\u4e25\u91cd\u4e0d\u826f\u4e8b\u4ef6\u3002<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n

CONCLUSIONS \u7ed3\u8bba<\/h3>\n\n\n\n

A combination of recombinant interferon beta-1b and lopinavir\u2013ritonavir led to lower mortality than placebo among patients who had been hospitalized with laboratory-confirmed MERS. The effect was greatest when treatment was started within 7 days after symptom onset.<\/p>\n\n\n\n

\u5bf9\u4e8e\u5b9e\u9a8c\u5ba4\u786e\u8bca\u7684MERS\u4f4f\u9662\u60a3\u8005\uff0c\u4e0e\u5b89\u6170\u5242\u76f8\u6bd4\uff0c\u8054\u5408\u91cd\u7ec4beta-1b\u5e72\u6270\u7d20\u548c\u514b\u7acb\u829d\u80fd\u591f\u964d\u4f4e\u75c5\u6b7b\u7387\u3002\u53d1\u75c57\u5929\u5185\u5f00\u59cb\u6cbb\u7597\u65f6\u7597\u6548\u66f4\u4e3a\u660e\u663e\u3002<\/p>\n\n\n\n

(Funded by the King Abdullah International Medical Research Center; MIRACLE ClinicalTrials.gov number, NCT02845843. opens in new tab<\/a>.)<\/p>\n","protected":false},"excerpt":{"rendered":"

ORIGINAL ARTICLE Interferon Beta-1b and Lopinavir\u2013Riton […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/19407"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19407"}],"version-history":[{"count":4,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/19407\/revisions"}],"predecessor-version":[{"id":19431,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/19407\/revisions\/19431"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19407"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19407"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}